Premium
Aggressive polychemotherapy for acute myelofibrosis
Author(s) -
Hertenstein B.,
Kurrle E.,
Frickhofen N.,
Heil G.,
Heimpel H.
Publication year - 1990
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1990.tb00382.x
Subject(s) - myelofibrosis , medicine , immunophenotyping , acute leukemia , daunorubicin , aplasia , megakaryocyte , pathology , leukemia , bone marrow , immunology , haematopoiesis , biology , flow cytometry , stem cell , genetics
Acute myelofibrosis is a rare and still ill‐defined disease. Based on morphological observation, immunophenotyping and ultrastructural analysis, we support the assumption that acute myelofibrosis is a malignant disorder mainly of the megakaryocyte lineage and is closely related to acute megakaryocytic/blastic leukaemia. Consequently, the 11 patients reported here were treated with aggressive polychemotherapy with combinations including daunorubicin and cytosine arabinoside and 6‐thioguanin or VP16–213. 4 complete remissions, 2 partial remissions and 1 minor response were observed. Duration of aplasia was not significantly prolonged. These findings indicate that the use of aggressive polychemotherapy is feasible in acute myelofibrosis and results in a significant number of remissions.